Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The United Laboratories International Holdings ( (HK:3933) ) has issued an update.
The United Laboratories International Holdings has received approval from China’s National Medical Products Administration to market its Insulin Degludec Injection in both refilled and disposable pen formats, targeting adult diabetes patients. Insulin degludec, an ultra-long-acting basal insulin already included in Category B of the 2025 National Medical Insurance Drug List, offers once-daily dosing with stable glycemic control and flexible administration.
The company describes the approval as a significant technological step in its diabetes portfolio and a reinforcement of its biopharmaceutical innovation strategy. Management expects that expanding its pipeline with higher-quality chronic disease therapies will enhance its competitiveness, support clinical practice, benefit patients, and ultimately create greater value for shareholders.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings is a Hong Kong-listed pharmaceutical group incorporated in the Cayman Islands, operating through subsidiaries such as Zhuhai United Bio-Pharmaceutical Co., Ltd. The company focuses on biopharmaceutical research, development, and manufacturing, with a strategic emphasis on chronic disease treatments, particularly in the diabetes segment.
YTD Price Performance: 13.89%
Average Trading Volume: 9,751,330
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$26.04B
Find detailed analytics on 3933 stock on TipRanks’ Stock Analysis page.